

## Senvelgo® diabetic consult checklist:

# Long-term management

For longer-term monitoring a recheck is required at 4 weeks after starting treatment, then every 3 months and immediately if the cat becomes unwell. Monitoring for the presence of ketones needs to be done at least at these timepoints but consider regular checks (e.g. via urine dipsticks at home).

### History:

*Is the cat well? Consider:*

- ☐ appetite
- ☐ thirst
- ☐ urination
- ☐ signs of lethargy
- ☐ vomiting
- ☐ diarrhoea

*Also check:*

- ☐ Senvelgo® administered as prescribed
- ☐ Any questions/general concerns

### Nutrition:

- ☐ Appropriate diet/volume

### Physical examination:

- ☐ Physical examination
- ☐ Weight/body condition score
- ☐ Hydration

### Tests:

- ☐ Urinalysis (to check for a urinary tract infection and ketones)
- ☐ Consider testing glycaemic control (e.g. fructosamine or spot glucose\*)
- ☐ Reassess whether tests for concomitant disease required

### Owner checklist:

*Items:*

- Senvelgo® prescribed
  - ☐ 12 ml bottle
  - ☐ 30 ml bottle
- ☐ Urine dipsticks +/- non-absorbable litter
- ☐ Senvelgo® Home Care Journal for recording of cat wellness and longer-term ketone monitoring

### Skills/knowledge:

- ☐ Administration technique
- ☐ Ketone testing
- ☐ Plan next appointment
- ☐ Understand importance of contacting vet if cat becomes unwell

\*Blood glucose can still be elevated due to stress hyperglycaemia.



Boehringer  
Ingelheim

## Guidance notes:

Senvelgo® should be administered once daily, at approximately the same time, either directly into the cat's mouth or via a small amount of food to ensure the entire dose is taken at once.

If the cat becomes ketonuric, unwell or has significant weight loss then suspend Senvelgo® treatment and investigate for underlying disease and treat appropriately.

If diabetic ketoacidosis (DKA) is suspected, stop treatment with Senvelgo® and treat the DKA as per standard protocols, including soluble insulin, intravenous fluid therapy and supplement with glucose/dextrose if blood glucose <15 mmol/l. Please be aware that cats on Senvelgo® may present with normal blood glucose levels, known as euglycaemic DKA (eDKA), but treatment principles remain the same.

## Senvelgo® vet website:

To learn more about Senvelgo® and to download the Vet Management Guide and owner leaflets, visit the product vet website:

GB: [senvelgo.co.uk](https://senvelgo.co.uk) IE/Northern Ireland: [senvelgo.vet](https://senvelgo.vet)

*Note: live chat service available on the 'Veterinary Support' page.*

To speak to one of our technical vets call our  
Vet Diabetes Helpline on:

UK: 01344 746 957 IE: 01 291 3985

Or email:

[vetenquiries@boehringer-ingelheim.com](mailto:vetenquiries@boehringer-ingelheim.com)



Senvelgo® contains velagliflozin (sodium-glucose co-transporter 2 [SGLT-2] inhibitor). UK: POM-V IE: POM. Further information available in the SPC or from Boehringer Ingelheim Animal Health UK Ltd., RG12 8YS, UK. UK Tel: 01344 746959 (sales) or 01344 746957 (technical), IE Tel: 01 291 3985 (all queries). Email: [vetenquiries@boehringer-ingelheim.com](mailto:vetenquiries@boehringer-ingelheim.com). Senvelgo® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under licence. ©2025 Boehringer Ingelheim Animal Health UK Ltd. All rights reserved. Date of preparation: Sep 2025. UI-PET-0253-2025.

Use Medicines Responsibly.

Prescription decisions are for the person issuing the prescription alone.